Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab-Reference-Cited by-同舟云学术

Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab

Published:2023-11 Issue: Volume: Page:
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Sousa Paula^ORCID,Patita Marta,Arroja Bruno,Lago Paula,Rosa Isadora^ORCID,de Sousa Helena Tavares,Ministro Paula,Mocanu Irina,Vieira Ana,Castela Joana,Moleiro Joana,Roseira Joana,Cancela Eugenia,Portela Francisco,Correia Luis,Santiago Mafalda,Dias Sandra,Alves Catarina,Afonso Joana,Dias Claudia Camila,Magro Fernando

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference27 articles.

1. Review article: emerging drug therapies in inflammatory bowel disease;Grossberg;Aliment Pharmacol Ther,2022

2. Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease;Verstockt;Gut,2021

3. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource;Stournaras;Gut,2021

4. Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease;Rezazadeh Ardabili;Aliment Pharmacol Ther,2022

5. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;New Engl J Med,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”;Digestive and Liver Disease;2024-03

2. Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?;Digestive and Liver Disease;2023-12